Aims Population data indicate that one in 25 persons of African ancestry has heart failure, a condition with relatively high mortality of around 50% in 5 years. Combined hydralazine and isosorbide dinitrate added to conventional therapy in African ancestry patients with heart failure and reduced ejection fraction improves quality of life and reduces the rate of first hospitalization for heart failure by 33% and annual mortality by 43%. The objectives of this study were to quantify the use of this guideline-recommended therapy in Europe and the potential effect of implementation gaps on mortality.
Introduction
Heart failure (HF) is a prevalent and deadly disease among persons of African ancestry (AA). According to the American National Heart, Lung and Blood Institute, one in 25 AA persons has HF. 1 The 5 years' fatality rate after incident hospitalization for HF per 1000 person-years is reported to be 52% in AA men and 46% in AA women. 2 HF in AA is of predominantly nonischaemic aetiology, and the more severe natural history is largely explained by a greater risk factor burden of obesity, hypertension, diabetes, and chronic kidney disease. [1] [2] [3] [4] [5] [6] [7] In addition, a distinct response to pharmacotherapy is noted, with low efficacy of angiotensin-converting enzyme inhibitor therapy, 4, 8, 9 which is thought to be associated with compromised bioavailability of nitric oxide (NO). 5, 9 In line with this notion, a retrospective analysis of the Vasodilator-Heart Failure Trial I indicated a significant survival benefit in AA but not European men when a combination of vasoactive drugs, hydralazine (H), an antioxidant that inhibits destruction of NO, and the NO donor isosorbide dinitrate (ISDN) was added to conventional therapy. In AA patients randomized to H + ISDN, the annual mortality ratio was 9.7% compared with 17.3% with placebo (À44%; P < 0.05), without significant difference in European patients. 10 The subsequent
African-American Heart Failure Trial (A-HeFT) in 1050 selfidentified AA patients with New York Heart Association Class III or IV HF with dilated ventricles confirmed these findings, with a 43% reduction in mortality with fixed-dose, single-pill H-ISDN vs. placebo during a mean follow-up period of 10 months (6.2 vs. 10.2%; P < 0.05). 11 In addition, a 33%
relative reduction in the rate of first hospitalization for HF (16 vs. 24%; P < 0.05), a significant reduction in exacerbation of congestive HF (9 vs. 13%), and improvement in quality-of-life scores vs. placebo were reported. Headache (48 vs. 19%) and dizziness (29 vs . 12%) were the most common adverse effects reported vs. placebo. 5, 11, 12 Although
American as well as European guidelines advise H and ISDN for self-described AA patients with New York Heart Association Class III-IV HF and reduced ejection fraction, 2, 5, [13] [14] [15] recent American studies have indicated that doctors do not prescribe this life-saving therapy to the majority of eligible hospitalized or outpatient AA patients. 5 Therefore, this study analyses the implementation of this evidence in medical practice across Europe. 
Methods

Design and definitions
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Outcomes
The primary outcome was the number of unique patients prescribed the fixed combination H-ISDN (as assessed in the A-HeFT). The secondary outcome was the use of both H + ISDN in unique patients as a proxy for the use of the combination. Tertiary outcomes were estimated health effects associated with prescription practices.
Hydralazine and isosorbide dinitrate
The European Society of Cardiology (ESC) 2012 Guidelines for treatment of HF advise combination therapy with H and ISDN for AA patients, but the drug combination is also advised with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker intolerance, to reduce the risk of hospitalization and risk of premature death in HF patients with ejection fraction ≤ 35% or ejection fraction ≤ 45% and a dilated left ventricle. 
Drug registration and utilization data
The Anatomical Therapeutic Chemical Classification (ATC) System codes for H and ISDN ( Estimation of heart failure prevalence and mortality in African-Europeans
Heart failure prevalence increases with age and risk factor burden and may vary by ethnicity, sex, education level, and diagnostic criteria. [1] [2] [3] 5, 7, 18, 20 In the absence of European data, the age-adjusted population prevalence in AA is estimated to be 4% based on US data.
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Annual HF mortality rates vary considerably across populations, with an average of 17%. 21 Cardiac and non-cardiac factors, including sex, age, ethnicity, differences in risk factor burden, recent hospitalization for acute HF, and health care characteristics, may affect mortality. The EU (national) data on mortality of AA with HF are not available. Data from the Duke Databank of Cardiovascular Disease 26 indicated adjusted mortality rates for HF in AA of 12% at 1 year and 49% at 5 years. In the Atherosclerosis Risk in Communities study, 76% of the prospectively followed AA population members with HF were hospitalized within 1.7 years, with an age-adjusted case fatality rate after the first hospitalization of 24% at 1 year in men and women, and 52% in men vs. 46% in women at 5 years. 22 Vasodilator-Heart Failure Trial I (only AA men), the annual mortality rate of HFrEF was 9.7 vs. 17.3% without receiving this therapy, 10 and in A-HeFT (AA men and women) using fixed combination H-ISDN, this was respectively 6.2 vs. 10.2%. 11 Based on the available data, the HF population prevalence in European AA persons is estimated 4%, with 50% HFrEF, and around 25-30% of all AA HF patients to benefit from H and ISDN therapy. 25 The number of eligible patients is assumed to be at steady state, with a linear benefit of therapy over time. 25 Annual mortality rates are conservatively estimated as 6% with and 10% without H and ISDN use, rounded to 100 persons.
Results
Despite the implementation in the ESC guidelines, H and ISDN use in the European nations surveyed appears to be negligible. Figures 1-4 and Table 2 summarize the estimated number of persons of AA and the registration and utilization of H-ISDN and its components from national drug registration and utilization databases in 25 European countries surveyed.
In 2015, more than 10 years after A-HeFT was published, the collected evidence indicates that no person in Europe had received fixed H-ISDN in that year and fewer than 500 received H + ISDN.
African populations
All European and national bodies approached replied to requests for data. Except for the UK, statistics bureaus stated not to collect governmental demographics by race/ethnicity. Main data sources to estimate the number of AA persons living in continental Europe at 12 million were national statistics bureaus' estimations based on country of birth (first and second generation migrant populations), data from the European Network Against Racism, nongovernmental organizations serving the AA population, scholarly papers, and online resources ( Figure 1 , Table 2 and the Appendix).
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Market authorization, availability, and use of hydralazine and isosorbide dinitrate
No published reports were retrieved documenting the use of H and ISDN in AA patients with HF in Europe. The fixed combination H-ISDN was not authorized at the EMA or within any European nation ( Figure 2 ). In addition, in many countries including France, commercially prepared oral H or oral ISDN 
490
L.M. Brewster was unavailable ( Figure 3 and Table 2 ). In general, magistral preparations were not nationally registered, but some countries, such as Norway and Sweden, do file every prescription, while others, such as Denmark and Belgium, filed medicine sales. Both Denmark and Belgium indicated that pharmacies' production volumes for individual patients would by EU law be very low.
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The total number of persons using the fixed combination H-ISDN in Europe was nil ( Table 2) . As neither H nor ISDN has a central (EU) market authorization, the combined use in countries was considered to be nil if oral H or oral ISDN did not have a national market authorization or were unavailable, but confirmation was requested at national bodies that register drug use. Poland and Latvia did not have data to confirm that no unique patient used both H and ISDN, but there was no market authorization for H in either country.
Of the five countries where both oral H and oral ISDN were available ( Figure 3 and Table 2 ), data from Norway and Sweden include all pharmaceutical drug sales (for Norway including hospital data), from Finland contain all reimbursed prescription drugs, while the UK and the Netherlands provided data on reimbursed drugs to outpatients only. With the focus on chronic care, >100 000 unique patients using these drugs were expected ( Table 2) . However, combined use of commercially available (pharmaceutical) H and ISDN in unique, non-hospitalized patients across Europe was negligible at <500 in 2015 (Figure 4) . Only Belgium reported the use of magistral preparations of H, in <250 patients in 2015.
Thus, less than 1% of European AA patients with HF could have received any combination of H and ISDN for chronic HF care ( Table 2) . At the expense of potential side effects, mainly headache and dizziness, the use of this drug combination might have substantially reduced premature mortality with 4800 to 5800 AA HF patients yearly.
Discussion
This study provides evidence of a significant care gap in best practice of HF treatment provided to persons of AA across Europe. Although there is evidence from randomized controlled trials and real-world studies on the reduction of HF Figure 3 Market authorization for both components H and ISDN. Plus (+) and minus (À) signs depict national market authorization for both components of H-ISDN, H (ATC C02DB02), and ISDN (ATC C01DA08). There is no centralized EU authorization for either drug, and a national market authorization for both components in only 5 of the 25 European nations surveyed (the UK, the Netherlands, and three Nordic countries). Spain only has sublingual isosorbide dinitrate available (5 mg). With an estimated African ancestry population of 12 million, >100 000 prescriptions are expected, but <500 patients received these drugs. Data from the UK (extrapolated from a 20% population sample) and the Netherlands are reimbursed drugs prescribed to outpatients. Norway and Sweden include all pharmaceutical drug sales (Norway including hospital data); Finland reports all reimbursed prescription drugs.
H and ISDN for heart failure in African-Europeans Because of this major discrepancy between best practice and care provided in usual clinical practice, 4800 to 5800 of African-European HF patients may die prematurely each year. This estimation is conservatively based on a 40% reduction in mortality with H-ISDN from 10 to 6%, while real-world data indicate that annual mortality rates in AA HF patients might be considerably higher, 18, 21, 22, 26 in particular when the fixed combination is not used. 18 These findings should have significant clinical and public health policy implications, to ensure that the ESC guideline-recommended therapy with H and ISDN 32 is applied and optimal care is provided to AA HF patients.
Strengths and limitations of this study
The study is to our knowledge the first to report the performance of European health care regarding H and ISDN, with negligible use as the main outcome. Although this study represents the best estimate of drug use, it required the gathering of data from heterogeneous sources that might have utilized different definitions and criteria for H and ISDN use and for being of 'sub-Saharan African ancestry'. Furthermore, there is a lack of data on drug dose and on prescription patterns in time or by age and sex, while data from European countries with very small AA populations were not exhaustively collected in this study. Also, many national bodies provided data on reimbursed drugs only. However, European countries have a universal health care system that provides health care and financial protection to >90% of the citizens. with high creatine kinase activity and creatine synthesis, and glucose-6-phosphate dehydrogenase deficiency have been suggested to induce low NO bioavailability, and assessments of these enzyme systems might help predict responses to H and ISDN. 9 Also, G-protein beta-3 subunit genotype was reported to predict the response to H and ISDN, 38 but to date, no biomarker has been validated for clinical use, and self-identified AA remains the best available predictor for benefit from H and ISDN therapy. 4, 5, [8] [9] [10] [11] The lack of consensus on categories based on ancestry and inconsistent data collection are major hindrances for European health outcome assessments by AA. This difficulty in assessing data extends the problem of a significant evidence-practice gap in the care of AA patients with HF.
Conclusions
This survey provides preliminary evidence that patients of AA in Europe with HF might experience excess mortality because of an unmet therapeutic need, as the guidelinerecommended, life-saving adjunctive combination therapy with H and ISDN is not available or not prescribed. Aside primary prevention of HF-in particular the early detection and adequate treatment of hypertension-access to and use of this life-prolonging therapy with H and ISDN are imperative to reduce premature mortality in AA patients with HF. 
